Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block. - Test2 - elhamkhani - TriplyDB

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

http://www.wikidata.org/entity/Q34985562

about

Targeting of erbB3 receptor to overcome resistance in cancer treatment The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.ErbB2 receptor immunoreactivity in prostate cancer: relationship to the androgen receptor, disease severity at diagnosis and disease outcome.Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3 Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis Affibody-mediated PET imaging of HER3 expression in malignant tumours.Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors.The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.Cell mates: paracrine and stromal targets for prostate cancer therapy.Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer.Her3 is associated with poor survival of gastric adenocarcinoma: Her3 promotes proliferation, survival and migration of human gastric cancer mediated by PI3K/AKT signaling pathway.Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule.Down-regulation of the ErbB3 binding protein 1 in human bladder cancer promotes tumor progression and cell proliferation.Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.An In Silico Evaluation of Deleterious Nonsynonymous Single Nucleotide Polymorphisms in the ErbB3 Oncogene.Advances in Targeting HER3 as an Anticancer Therapy Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma.Evaluation of Protein Levels of the Receptor Tyrosine Kinase ErbB3 in Serum.Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics.Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.Decline in Arylsulfatase B Expression Increases EGFR Expression by Inhibiting the Protein Tyrosine Phosphatase SHP2 and Activating JNK in Prostate Cells.Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells

P2860

Q26864668-33856701-207B-4B4D-938D-47228F8C2F5C Q30845020-E0224FFB-79D3-432F-90CF-3697505133DF Q33352155-E9817A35-413C-4E9B-A371-EC3D4332145F Q34172262-D52D59AE-FB53-4413-8147-CE47EBACFFB1 Q35269318-48DA4FEE-3984-4B06-96A3-C8CAD031FBE3 Q36071752-A5A4CDE5-2A0E-4C82-913A-6389CEBDE6C2 Q36106546-453EAE81-10A0-4C42-91FF-00BA3D75A917 Q36174716-93E6046E-2DCC-4309-B125-16A41B623AFA Q36396421-39B2A7E4-EF0C-43CD-BC0C-850C0C7F5F6C Q36475900-C5EF790B-B17B-47F1-B69A-C514E01E3CCD Q37312071-29AA972A-FB03-4465-A7AC-E03BD5225866 Q37968256-2B321D78-87B3-423A-B085-BAB6D8033BFA Q38121792-7F39E546-3752-491F-A371-ABC80C155729 Q38262816-14A2297B-1D12-463C-8815-B6C399928CC7 Q38729111-FB99F29C-2353-4325-862D-C2F28D782714 Q38864254-75FCD3A9-2D6A-4B12-8DA9-3371F4657045 Q38929801-4E72046C-A2D7-4F1E-9C55-5F75C6965D2C Q38932495-6795EDA3-F45E-47A6-9E16-E66EBE80EDA4 Q38940200-92010AFE-E697-4ED3-A87F-269E01EF1E0E Q39016174-62BDB471-5A6A-472E-8982-95F5D0CC6823 Q39016180-946C0E47-CB04-4A64-B481-DCADAE5C8A66 Q39217541-E36C7C6F-EDFF-4A06-AE51-153987895D3E Q39257661-6173F05D-4605-455F-A10D-C54A99A4D5BD Q40452694-9639F524-67B8-41FE-9815-19100B1E3A7F Q41133462-B1705ED0-31FF-4591-804A-39A9D74F343B Q41621146-616A39BA-7300-4FD3-9AA4-99A14A52E1C4 Q46495042-EEA3A053-BF07-4522-B37E-1FF75CCCACAB Q46942173-49C83BE8-F98E-4885-9272-9360C4EA9740 Q47243379-2F761AD0-743A-47FA-A72E-8AAE14D2FF23 Q54301350-21206286-50FA-4DA2-B394-DEF2EFEB1293 Q54978374-4818D131-B6E0-46C3-B685-7DAD48247A22 Q58796351-00DB2330-2C8F-485A-82B3-C76EE8991195

P2860

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

http://www.wikidata.org/entity/Q34985562

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Targeting ErbB3: the New RTK

@nl

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

@ast

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

@en

type

label

Targeting ErbB3: the New RTK

@nl

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

@ast

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

@en

prefLabel

Targeting ErbB3: the New RTK

@nl

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

@ast

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

@en

P1433

Q34985562-032A3767-7F49-41C6-97B4-909C2250308C

P1476

Q34985562-F40C29DE-F7D5-4EE1-B416-A2E30F99F51C

P2093

Q34985562-1CC2D088-FC4B-420A-B5C4-BE6507CBACC4

Q34985562-66826198-1367-4E6B-B575-AE1ED424DA15

Q34985562-A83F90E0-564D-4636-9DC0-E91EEB48FC4D

Q34985562-AAC680E0-3764-4834-8456-E60CAF4EF8E9

P2860

Q34985562-00992005-8285-4A74-9917-FA9AA75A5462

Q34985562-027D892D-AC20-4C41-987B-A952D75738AF

Q34985562-05DBB9EE-6F7A-4918-8844-2387D3A6DA47

Q34985562-05F5F9D7-53B0-4CD4-A75D-C7A754EB48B8

Q34985562-072E9CCE-8457-48C2-B4F2-AC66B41B96DC

Q34985562-07CE1031-D840-4BEC-9E32-654381257312

Q34985562-084677FD-26BB-43A5-A991-874C3EDDC84B

Q34985562-085BB999-F65C-4C59-B70A-CBFB95F7B02C

Q34985562-08EA5EA2-1E2D-4940-A927-05EF7688DE64

Q34985562-0BB213D9-C6F9-476F-B25A-228A234C4C82

P304

Q34985562-7DF07DE3-B29E-48B2-906E-F75FAB1B99A0

P31

Q34985562-0C71E12F-58D9-4547-9E37-4D6E9C886A5A

P356

Q34985562-1099373F-B0C0-4793-83F9-DA712D9CEDDB

P433

Q34985562-D2B45DE4-8C85-48EF-A2D1-50C6D1D99866

P478

Q34985562-8E181233-B4DF-499C-B64C-0A18B01D1BF7

P577

Q34985562-C3EFA058-AA06-4D3B-8594-1BFADBBC4588

P5875

Q34985562-D0144955-705D-4C31-8BE9-22CD960415FB

P698

Q34985562-89660627-63E6-4BD0-A7FE-44790A719C52

P932

Q34985562-0CA5CDF9-EFAB-42BA-B091-C5C4578F8E95

P356

187152211795495643

P1433

Immunology, endocrine & metabolic agents in medicinal chemistry

P1476

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

@en

P2093

Liqun Chen

http://www.w3.org/2001/XMLSchema#string

Maitreyee K Jathal

http://www.w3.org/2001/XMLSchema#string

Maria Mudryj

http://www.w3.org/2001/XMLSchema#string

Paramita M Ghosh

http://www.w3.org/2001/XMLSchema#string

P2860

A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4

An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels

Ebp1 isoforms distinctively regulate cell survival and differentiation

Stabilization of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth

A tyrosine kinase profile of prostate carcinoma

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance

P304

131-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/187152211795495643

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51156644

http://www.w3.org/2001/XMLSchema#string

P698

21603064

http://www.w3.org/2001/XMLSchema#string

P932

3095967

http://www.w3.org/2001/XMLSchema#string